Longeveron Inc LGVN

$2.58 -0.01 (-0.39%)

Valuation

Market cap
8,226,000
Revenue TTM
$1,200,000
Net income TTM
$-22,700,000
PE ratio
0.00
Forward PE
—
Profit margin
-1,891.67%
Debt to equity
0.00

Trading

Volume
20,800
Avg volume
109,903
Day's range
$2.54 – $2.67
Shares out
3,188,000
Stochastic %K
40%
Beta
-0.19
Analysts
Hold
Price target
$4.25

Price

Company profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clini...

Show more

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
844 470 2550
Website
https://longeveron.com
Address
Life Science & Technology Park, Suite 520 1951 NW 7th Avenue, Miami, United States

Latest news

Stocktwits

BSinvest Oct 2, 6:03 AM
$LGVN this could be the field that boom like all the ai stocks did. Ai could enhance this rapidly over the coming years buying this could be like buying Nvidia at 2 bucks. I’ll buy 10k shares just in case.
1 replies
skyrockets_Inc Sep 30, 9:38 PM
$LGVN "The Company intends to pursue funding sources and other potential revenue opportunities to advance laromestrocel in longevity and Aging-related Frailty" https://investors.longeveron.com/news/News/news-details/2026/Longeveron-to-Participate-in-Three-LongevityAging-Investment-Conferences/default.aspx
0 replies
Abdul92z Sep 24, 10:00 PM
$BRNX , $LGVN , $CYCU lets see
0 replies
skyrockets_Inc Sep 24, 8:00 PM
$LGVN strong day and close.... interesting action.
1 replies
skyrockets_Inc Sep 24, 6:38 PM
$LSTA For my fellow Lisata-ians, I see $LGVN now as the new LSTA when LSTA was trading at $1.0/share. See my post in the LGVN chat but I think it's a great opportunity for those looking to slowly shift out of LSTA into another similar play. Cash strapped strategic alternative play w/ a more valuable drug than Certepetide imo.
0 replies
skyrockets_Inc Sep 24, 3:52 PM
$LGVN The reverse merger valuation theory..... Recent reverse merger transacations of various companies below and the value given to their shells (net of cash). The median shell valuation was around 10m. If LGVN gets 10m valuation for shell and has net cash of (-5m) at closing, valuation of shell will be 5m / 3.2 OS = 1.6/share FLOOR for shell only . Add in value of laromestrocel at 5m conservative and you get back to 10m / 3.2m or 3.2/share. So downside risk from these levels of ~30% and upside potential of whatever drug is worth. I'm a continuous buyer at these levels.
0 replies
Naser111111 Sep 23, 10:45 AM
$LGVN Don’t judge $LGVN solely by the ELPIS II results! Its Laromestrocel therapy for age-related frailty improved 6-minute walking distance by 63.4 meters versus placebo (p=0.0077) in a clinical trial involving 148 participants. $LGVN was among 10 teams awarded $1M in the XPRIZE Healthspan competition, selected from over 600 applicants. It has advanced to compete for prizes totaling up to $81M—a strong endorsement of its frailty program’s potential, though broader efficacy remains to be proven.
0 replies
Market_Pulse_Report Sep 22, 10:54 PM
$LGVN Check out the analysis, went over all of the FINANCIALS https://youtu.be/a6S7qv9EvfM
0 replies